(RTTNews) - Cognition Therapeutics (CGTX), a clinical-stage biopharmaceutical company, announced on Thursday positive results from its Phase 2 SHIMMER study of Zervimesine or CT1812 in dementia with Lewy bodies or DLB.
The study demonstrated significant therapeutic responses in patients with mild-to-moderate DLB, with Zervimesine-treated participants showing 86 percent better behavioral outcomes, 52 percent improvement in activities of daily living, 91 percent reduction in cognitive fluctuations, and 62 percent better motor function compared to placebo.
These improvements across multiple symptom domains highlight Zervimesine's potential to address the complex and rapidly progressing nature of DLB, a disease with no current disease-modifying treatments.
The SHIMMER study met its primary endpoint of safety and tolerability, with Zervimesine showing a favorable safety profile. The results will be presented by Dr. James E. Galvin, the study's principal investigator, during an oral presentation at the International Lewy Body Dementia Conference or ILBDC on January 31, 2025.
Cognition's Chief Medical Officer, Dr. Anthony O. Caggiano, emphasized that Zervimesine's positive effects on cognitive, behavioral, and motor symptoms could provide significant relief for DLB patients, potentially allowing them to remain at home longer with the support of caregivers.
The company is continuing to advance its clinical programs, with Zervimesine being studied in both DLB and Alzheimer's disease.
Currently, CGTX is trading at $0.75 down by 0.70%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
